Evaluation of imatinib (GLIVEC) after induction therapy in patients aged more than 55 years with Philadelphia positive acute lymphoblastic leukaemia (Ph+ ALL): a non randomised, controlled, open, multicentric, international phase II clinical study (CSTI 571 AFR09 trial)

Trial Profile

Evaluation of imatinib (GLIVEC) after induction therapy in patients aged more than 55 years with Philadelphia positive acute lymphoblastic leukaemia (Ph+ ALL): a non randomised, controlled, open, multicentric, international phase II clinical study (CSTI 571 AFR09 trial)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2005

At a glance

  • Drugs Imatinib (Primary) ; Antineoplastics; Corticosteroids; Cyclophosphamide; Daunorubicin; Vincristine
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top